Why did you participate in the Biomapas Academy?
Everything started when I had a trip to a career fair during my studies. This was the first time I met Biomapas in person as there were several lecturers that presented the company itself and its activities. I remember thinking that I would like to work with this team as it piqued my interest.
Later, when I was working on my master’s degree, I came across an advertisement on social media for the Biomapas Academy. I already knew that I wanted to learn more about the pharma industry and was interested in various opportunities, so I applied for this opportunity.
How was your experience during the three months?
The Academy was a continuous cycle spanning several months of interesting lectures from true professionals with extensive knowledge. During this short time, I learned a lot about product development, research, safety information and its systems, different possible roles and their responsibilities, and new opportunities where young specialists can grow and find their place in the life sciences industry.
What did the future hold for you after the Academy?
A while after the Academy, I officially became part of Biomapas and its big family! With my background being an MPharm, I was always interested in drug safety. Therefore, I am working in the Pharmacovigilance Department as a Pharmacovigilance Project Management Assistant. I must say there are many interesting things to learn and experience that I am looking forward to with my team.
What would you say to the future participants?
If you are thinking about participating in the Academy, do not hesitate. Being an alumnus, I can say that you will definitely see the pharma industry from within. It will broaden your understanding; you will gain needed knowledge and experience in life sciences and will be able to apply that information working in your chosen field. I hope to see you at Biomapas!
Biomapas Academy
What is Clinical Research? Regulatory Affairs? Pharmacovigilance?
Biomapas Announces Strategic Partnership to Drive Future Growth
Carbyne Equity Partners has signed to acquire majority ownership in UAB Biomapas.
Diversity in Clinical Trials: Significance & Challenges
Diversity in Clinical Trials: Significance & Challenges By Jan Filakovsky, CEO of BiomapasDiversity in clinical trials is crucial in ensuring that research findings are broadly applicable, and in avoiding treatments that are ineffective or even harmful to...
Partnering for Success: Specialised Rescue Studies in Georgia
Discover the benefits of conducting clinical trials in Georgia through this case study of three pharmaceutical companies.
Unlocking Success: The FSP Advantage in Clinical Research
The Functional Service Provider (FSP) models in clinical research are becoming increasingly appealing to the pharmaceutical and biotechnology sectors, offering flexible and scalable solutions to outsource specific functions . Currently pharmaceutical and...
Literature monitoring of Pharmacovigilance in realities of war in Ukraine
The need for continuous monitoring of drug safety in a country at war, and the ability to adapt to the circumstances for ensuring the safety of patients, is critical.
Bridging Gaps in Clinical Trials: Enhanced Access & Embracing Diversity
Explore the crucial role of diversity and accessibility in clinical research in this insightful article.
Pharmacovigilance & CSV: System Upgrades
Explore the intersection of Pharmacovigilance & CSV during system upgrades. Ensure drug safety while optimizing computer system validation.
Adaptive Clinical Trials
What are Adaptive Clinical Trials? And how can we leverage their distinguished ability to evolve to improve clinical designs?
CSV & Risk Management in Pharmacovigilance
CSV & Risk Management Pharmacovigilance stands as a guardian in drug development and monitoring, ensuring that medicines remain safe and effective throughout their lifecycle. But behind this sentinel lies a complex web of systems, processes, and regulations, each...
Clinical Endpoints In Early Phase Oncology Trials
Clinical Endpoints In Early Phase Oncology Trials: Discover their influence on safety, study design, and regulatory compliance.
